|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:clinical_trial
|
thousands
multiple countries
pending
Phase 2
|
|
gptkbp:clinical_trial_phases_completed
|
Phase 1
|
|
gptkbp:collaboration
|
gptkb:GSK
|
|
gptkbp:community_health
|
potential to reduce COVID-19 cases
|
|
gptkbp:developed_by
|
gptkb:Cure_Vac_AG
|
|
gptkbp:dosage_form
|
two doses
|
|
gptkbp:first_clinical_trial_start_date
|
gptkb:2020
|
|
gptkbp:funding
|
government grants
public and private investment
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cure Vac CVn Co V
|
|
gptkbp:immune_response_type
|
humoral and cellular
|
|
gptkbp:is_effective_against
|
not yet determined
|
|
gptkbp:is_vulnerable_to
|
global
varied
ongoing
messenger RNA
logistical issues
accelerated due to pandemic
|
|
gptkbp:mechanism_of_action
|
induces immune response
|
|
gptkbp:partnerships
|
various pharmaceutical companies
|
|
gptkbp:platform
|
m RNA technology
|
|
gptkbp:regulatory_approval_status
|
not approved
|
|
gptkbp:research
|
completed
|
|
gptkbp:research_focus
|
COVID-19 prevention
|
|
gptkbp:research_institutes
|
multiple universities
|
|
gptkbp:route_of_administration
|
intramuscular
|
|
gptkbp:safety_features
|
under evaluation
|
|
gptkbp:side_effect
|
under investigation
|
|
gptkbp:status
|
under development
|
|
gptkbp:target_audience
|
adults
|
|
gptkbp:targets
|
gptkb:COVID-19
|
|
gptkbp:technology
|
lipid nanoparticle delivery system
|
|
gptkbp:type
|
gptkb:vaccine
|
|
gptkbp:vaccine_administration_frequency
|
two doses required
|
|
gptkbp:vaccine_approval_process
|
requires regulatory review
|
|
gptkbp:vaccine_candidate
|
yes
|
|
gptkbp:vaccine_clinical_trial_design
|
randomized controlled trial
|
|
gptkbp:vaccine_clinical_trial_outcomes
|
to be determined
|
|
gptkbp:vaccine_development_challenges
|
mutations of virus
|
|
gptkbp:vaccine_efficacy_monitoring
|
ongoing
|
|
gptkbp:vaccine_efficacy_study
|
ongoing
|
|
gptkbp:vaccine_global_health_impact
|
significant potential
|
|
gptkbp:vaccine_manufacturing
|
Cure Vac facilities
|
|
gptkbp:vaccine_public_health_goals
|
achieve herd immunity
|
|
gptkbp:vaccine_regulatory_pathway
|
emergency use authorization
|
|
gptkbp:vaccine_research_collaborations
|
international partnerships
|
|
gptkbp:vaccine_research_ethics
|
adhering to guidelines
|
|
gptkbp:vaccine_research_goals
|
improve efficacy and safety
|
|
gptkbp:vaccine_research_updates
|
regularly published
|
|
gptkbp:vaccine_storage_requirements
|
standard refrigeration
|
|
gptkbp:vaccine_storage_temperature
|
2 to 8 degrees Celsius
|
|
gptkbp:vaccine_target_antigen
|
gptkb:SARS-Co_V-2_spike_protein
|
|
gptkbp:bfsParent
|
gptkb:Cure_Vac
|
|
gptkbp:bfsLayer
|
4
|